Trevi Therapeutics Q1 net loss widens as R&D costs rise

Trevi Therapeutics

05/05/2026 21:53

Overview

U.S. biopharma firm's Q1 net loss widened as R&D and G&A expenses increased

Company completed $162 mln stock offering, extending expected cash runway into 2030

Clinical development plans for Haduvio remain on track across all chronic cough indications

Outlook

Trevi expects to initiate two Phase 3 trials in IPF-related chronic cough in H2 2026

Company expects topline results from first IPF-related chronic cough Phase 3 trial in H1 2028

Trevi projects cash runway into 2030, potentially through FDA approval of Haduvio in IPF-related cough

Result Drivers

R&D SPENDING - Higher R&D expenses driven by increased clinical development costs for Phase 1, Phase 3 IPF-related chronic cough, and Phase 2b RCC trials

G&A COSTS - G&A expenses rose due to higher legal fees for intellectual property filings and increased stock option and personnel expenses

INTEREST INCOME - Other income rose due to higher interest income from larger cash and marketable securities balances

Company press release: ID:nGNX4ZHrcd

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-$0.09
Q1 Net Income
-$13.19 mln
Q1 Income from Operations
-$14.91 mln
Q1 Operating Expenses
$14.91 mln
Q1 Pretax Profit
-$13.21 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Trevi Therapeutics Inc is $22.50, about 56.5% above its May 4 closing price of $14.38

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)